Skip to main contentSkip to navigation
Sirius Investors

NEUP Stock: Neuphoria Therapeutics Inc. Stock Price, Analysis & Insights

Get live NEUP stock price $4.38, comprehensive Neuphoria Therapeutics Inc. stock analysis, charts, news, and expert forecast. Real-time NEUP stock data and investment insights.

4.38
6.12%Today
NEUPNeuphoria Therapeutics Inc. • NASDAQ Global Market • Healthcare
Market Cap
23.64M
Volume
46.21K
52W High
21.40
52W Low
3.65

Loading chart data...

Investment Score

Annual (latest period)
Unavailable

A systematic tri-factor framework that integrates valuation, business quality, and market momentum into one investment signal. This helps investors triage opportunities faster, while surfacing risk regimes that may require tighter position sizing or deeper due diligence.

Score unavailable for this asset.

0-39

Defensive posture

40-54

Mixed / wait for confirmation

55-69

Constructive setup

70-100

Attractive zone

Total Score

Value

Cheapness vs fundamentals and cash generation

Quality

Durability of profitability and balance sheet

Momentum

Price trend strength and persistence

Professional usage: treat the score as a ranking and risk-filtering tool, then confirm with earnings revision trend, competitive positioning, and valuation relative to peers before capital allocation.

Company Overview

Neuphoria Therapeutics, Inc. is a biotechnology company currently advancing treatments through clinical trials. Its core mission involves pioneering therapies specifically engineered to address the intricate requirements of individuals living with ne...

Company Information

CEO
Spyridon Papapetropoulos
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Employees
8

Contact Information

Address
100 Summit Dr
Country
US

Investment Analysis & Business Insights

Healthcare
Medical - Pharmaceuticals

Investment Highlights

Strong presence in the Healthcare sector with established market position

Lower volatility stock (Beta: 0.72) may provide portfolio stability

Important Investment Considerations

  • All investments carry risk, including potential loss of principal for Neuphoria Therapeutics Inc. shareholders
  • Market volatility can significantly impact stock price, especially for smaller companies
  • Sector-specific risks in Healthcare may affect company performance
  • Past performance does not guarantee future results for Neuphoria Therapeutics Inc.
  • Investors should consider how Neuphoria Therapeutics Inc. fits within their overall portfolio allocation
  • Valuation metrics suggest potential, but require fundamental analysis

Market Cap

23.64M

P/E Ratio (TTM)

-0.55

Beta

0.72

Data Sources & Methodology

Financial data on this page is sourced from verified SEC EDGAR filings (10-K, 10-Q, 8-K reports), real-time market data providers, and official company disclosures. All analysis is generated using AI models trained exclusively on reliable financial documents. For detailed information about our data sources and methodology, see our Methodology page.Not investment advice.

About Healthcare Sector

The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.